Robeco Institutional Asset Management B.V. Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Robeco Institutional Asset Management B.V. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 26.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 172,328 shares of the company's stock after selling 60,432 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.21% of IDEXX Laboratories worth $71,247,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. Algert Global LLC grew its position in shares of IDEXX Laboratories by 70.0% in the 2nd quarter. Algert Global LLC now owns 709 shares of the company's stock valued at $345,000 after acquiring an additional 292 shares during the period. NewEdge Advisors LLC grew its position in IDEXX Laboratories by 36.4% during the second quarter. NewEdge Advisors LLC now owns 9,400 shares of the company's stock worth $4,580,000 after buying an additional 2,506 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in IDEXX Laboratories by 14.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,118 shares of the company's stock valued at $1,031,000 after purchasing an additional 260 shares in the last quarter. Quarry LP boosted its position in shares of IDEXX Laboratories by 170.8% during the 2nd quarter. Quarry LP now owns 176 shares of the company's stock worth $86,000 after acquiring an additional 111 shares in the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of IDEXX Laboratories by 0.8% in the 2nd quarter. Cetera Investment Advisers now owns 20,290 shares of the company's stock valued at $9,885,000 after purchasing an additional 161 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IDXX shares. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Piper Sandler reissued a "neutral" rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $517.29.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $5.24 during trading hours on Thursday, hitting $423.99. 507,653 shares of the company were exchanged, compared to its average volume of 684,887. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The stock has a market capitalization of $34.72 billion, a price-to-earnings ratio of 40.89, a P/E/G ratio of 3.63 and a beta of 1.36. The business has a 50-day moving average of $423.93 and a 200-day moving average of $454.80.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $2.53 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.